Diabetes Care, Vol 20, Issue 10 1576-1581, Copyright © 1997 by American Diabetes Association

ARTICLES

Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria

J Ahmad, MA Siddiqui and H Ahmad
Department of Medicine, Jawahar Lal Nehru Medical College and Hospital, Aligarh Muslim University, India.

OBJECTIVE: This study determines the long-term efficacy of the ACE inhibitor, enalapril, in reducing the progression of microalbuminuria to clinical albuminuria in normotensive patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: There were 103 normotensive type 2 diabetic patients with persistent albumin excretion rate (AER) 20-200 micrograms/min and normal renal function followed for 5 years in a prospective randomized single-blind placebo-controlled trial. AER, blood pressure, fasting plasma glucose, and HbA1 were measured very 3-4 months and glomerular filtration rate (GFR), renal plasma flow (RPF), and urinary urea every 12 months. RESULTS: In the patients treated with enalapril, AER decreased from 55 +/- 33 to 20 +/- 59 micrograms/min (geometric mean +/- SD), whereas in the placebo group, AER increased from 53 +/- 31 to 85 +/- 90 micrograms/min after 5 years. Within 5 years, 7.7% (4/52) of enalapril-treated subjects and 23.5% (12/51) of placebo-treated subjects progressed to clinical albuminuria defined as AER > 200 micrograms/min and at least 34% above baseline (risk reduction = 66.7%, P < 0.001). AER increased at an annual rate of 12.3% (95% CI 9.8-14.9) in the placebo group, while it declined by 16.7% (95% CI -18.3 to -15.2) in the enalapril group (P < 0.001). In addition, 8 of the 12 placebo-treated patients had evidence of coronary artery disease. The rest of the parameters remained practically unchanged in the two groups. CONCLUSIONS: After 5 years of therapy with enalapril, compared with placebo, normotensive subjects with type 2 diabetes experienced significantly less progression of microalbuminuria to clinical albuminuria, reduced AER, and preserved GFR.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. M Campbell, K. D Boardman, M. A Dodd, and D. W Raisch Pharmacoeconomic Analysis of Angiotensin-Converting Enzyme Inhibitors in Type 2 Diabetes: A Markov Model Ann. Pharmacother., July 1, 2007; 41(7): 1101 - 1110. [Abstract] [Full Text] [PDF]

				M. L. Caramori, P. Fioretto, and M. Mauer Enhancing the Predictive Value of Urinary Albumin for Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2006; 17(2): 339 - 352. [Abstract] [Full Text] [PDF]

				A. B. Rosen, M. B. Hamel, M. C. Weinstein, D. M. Cutler, A. M. Fendrick, and S. Vijan Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes Ann Intern Med, July 19, 2005; 143(2): 89 - 99. [Abstract] [Full Text] [PDF]

				M. Ravera, E. Ratto, S. Vettoretti, D. Parodi, and G. Deferrari Prevention and Treatment of Diabetic Nephropathy: The Program for Irbesartan Mortality and Morbidity Evaluation J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S48 - S52. [Abstract] [Full Text] [PDF]

				P. Gaede, L. Tarnow, P. Vedel, H.-H. Parving, and O. Pedersen Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2784 - 2788. [Abstract] [Full Text] [PDF]

				A. A.M. Zandbergen, M. G.A. Baggen, S. W.J. Lamberts, A. H. Bootsma, D. de Zeeuw, and R. J.Th. Ouwendijk Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial Ann Intern Med, July 15, 2003; 139(2): 90 - 96. [Abstract] [Full Text] [PDF]

				G. Wolf and E. Ritz Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1396 - 1405. [Full Text] [PDF]

				S. Vijan and R. A. Hayward Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care Ann Intern Med, April 1, 2003; 138(7): 593 - 602. [Abstract] [Full Text] [PDF]

				G. Deferrari, M. Ravera, L. Deferrari, S. Vettoretti, E. Ratto, and D. Parodi Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus: Angiotensin II Receptor Blockers J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S224 - 229. [Abstract] [Full Text]

				H.-H. Parving, N. Chaturvedi, G. Viberti, and C. E. Mogensen Does Microalbuminuria Predict Diabetic Nephropathy? Diabetes Care, February 1, 2002; 25(2): 406 - 407. [Full Text]

				B. M. Brenner, M. E. Cooper, D. de Zeeuw, W. F. Keane, W. E. Mitch, H.-H. Parving, G. Remuzzi, S. M. Snapinn, Z. Zhang, S. Shahinfar, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy N. Engl. J. Med., September 20, 2001; 345(12): 861 - 869. [Abstract] [Full Text] [PDF]

				G. J. Wehbi, J. Zimpelmann, R. M. Carey, D. Z. Levine, and K. D. Burns Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors Am J Physiol Renal Physiol, February 1, 2001; 280(2): F254 - F265. [Abstract] [Full Text] [PDF]

				A Melville, R Richardson, D Lister-Sharp, and A McIntosh Complications of diabetes: renal disease and promotion of self-management Qual. Saf. Health Care, December 1, 2000; 9(4): 257 - 263. [Full Text]

				B. M Brenner, M. E Cooper, D. de Zeeuw, J.-P. Grunfeld, W. F Keane, K. Kurokawa, J. B McGill, W. E Mitch, H. H. Parving, G. Remuzzi, et al. The losartan renal protection study -- rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 328 - 335. [Abstract] [PDF]

				T. Nakamura, C. Ushiyama, S. Suzuki, M. Hara, N. Shimada, I. Ebihara, and H. Koide Urinary excretion of podocytes in patients with diabetic nephropathy Nephrol. Dial. Transplant., September 1, 2000; 15(9): 1379 - 1383. [Abstract] [Full Text] [PDF]

				C. T. Valmadrid, R. Klein, S. E. Moss, and B. E. K. Klein The Risk of Cardiovascular Disease Mortality Associated With Microalbuminuria and Gross Proteinuria in Persons With Older-Onset Diabetes Mellitus Arch Intern Med, April 24, 2000; 160(8): 1093 - 1100. [Abstract] [Full Text] [PDF]